The Psychedelic Gold Rush: Five Companies Positioned to Win Under Trump's Executive Order

President Trump's executive order signed April 18 isn't just a policy signal — it's a structural catalyst for an entire class of drug developers that have spent years burning cash in regulatory limbo. The order directs the FDA to issue National Priority Vouchers to psychedelics with Breakthrough Therapy designations, instructs the DEA to create Right to Try pathways for investigational compounds including ibogaine, and allocates $50 million through ARPA-H to match state investments in psychedelic research. Combined with ARPA-H's existing $100 million EVIDENT initiative targeting rapid-acting behavioral health therapeutics, the federal government has committed $150 million to accelerating the science.

Monday's market reaction was immediate. The AdvisorShares Psychedelics ETF (PSIL) surged as much as 20%, hitting its highest intraday level since July 2023. But not all psychedelic companies are created equal. The ones positioned to benefit most have late-stage clinical programs, FDA Breakthrough Therapy designations, and compounds that align directly with the EO's priorities: treatment-resistant depression, PTSD, and veteran mental health.

Here's who stands to gain the most — and why.

Compass Pathways (NASDAQ: CMPS) — The Frontrunner

Compass is the closest to the finish line. The company's COMP360 synthetic psilocybin hit its primary endpoint in both Phase 3 trials for treatment-resistant depression — making it the first classic psychedelic to deliver Phase 3 efficacy data. The company has FDA Breakthrough Therapy designation, is pursuing a rolling NDA submission, and says it could be launch-ready by end of 2026.

The EO is tailor-made for Compass. National Priority Vouchers could compress the FDA's review timeline from the standard 10-month window to potentially weeks — the same mechanism that fast-tracked a weight-loss drug earlier this year. Compass CEO Kabir Nath called the order a moment where "regulatory urgency" meets "patient need." The company also has a Phase 2b/3 trial underway for PTSD, directly aligning with the EO's veteran-focused framing.

Shares surged as much as 53% Monday and closed up 42% — the stock's best day on record. With a rolling submission underway and the regulatory environment now actively accelerating, Compass is no longer just the frontrunner; it's pulling away from the field.

AtaiBeckley (NASDAQ: ATAI) — The Platform Play

AtaiBeckley isn't betting on one compound — it's building a platform. Formed from the 2025 merger of atai Life Sciences and Beckley Psytech, the company has three clinical-stage programs spanning psilocybin, 5-MeO-DMT, and MDMA derivatives, plus a significant equity stake in Compass Pathways.

The lead asset is BPL-003, a deuterated psilocybin analog for treatment-resistant depression. Phase 2a data showed roughly two-thirds of patients responding by Day 2, with most maintaining that response through Week 12 — critically, while staying on their existing SSRIs. The FDA granted Breakthrough Therapy designation and aligned on a Phase 3 design at an End-of-Phase-2 meeting in March 2026, with trials set to begin in Q2. VLS-01, a 5-MeO-DMT candidate, also holds Breakthrough Therapy designation and has Phase 2 data expected in H2 2026.

Deutsche Bank initiated coverage with a Buy rating and $12 target, and the company's $150 million cash position extends its runway through 2029. The diversified pipeline is the key differentiator — if one compound stumbles, the portfolio absorbs the hit. Monday's rally: shares up 21-28% depending on the session window.

GH Research (NASDAQ: GHRS) — The Speed Play

GH Research is pursuing what might be the fastest-acting psychedelic in development. GH001, an inhaled formulation of mebufotenin (5-MeO-DMT), delivered a 15.2-point reduction in depression scores by Day 8 versus a 0.3-point change for placebo in Phase 2b — a 15.5-point placebo-adjusted difference that is, by psychiatric drug standards, extraordinary. Remission rate: 57.7% on the active drug versus 0% on placebo.

The practical appeal is the treatment model: a single dosing day, with effects onset in roughly 15 minutes, and patients potentially dischargeable the same day. No multi-session psychotherapy protocols. No weeks of titration. The FDA lifted a clinical hold on GH001 in late 2025, clearing the path for global Phase 3 initiation in 2026. The company is also running trials in bipolar II disorder and postpartum depression.

GH Research's Phase 2b results were published in JAMA Psychiatry — a stamp of scientific credibility that separates it from earlier-stage speculation. Monday: shares jumped as much as 34%.

Definium Therapeutics (NASDAQ: DFTX) — The Anxiety Disruptor

Formerly MindMed, Definium rebranded in January 2026 to signal its evolution from a retail-investor darling into a serious clinical-stage company. The lead asset is DT120, an orally disintegrating tablet formulation of LSD being developed for generalized anxiety disorder and major depressive disorder — two conditions affecting over 50 million Americans combined.

The Phase 2 data was strong: a 21.9-point HAM-A reduction with 50% remission at 12 weeks from a single 100 µg dose. Three Phase 3 trials are running simultaneously, with the MDD readout (Emerge) expected late Q2 2026, the first GAD trial (Voyage) in early Q3, and the second GAD trial (Panorama) in H2. If the data holds, Definium would be entering the anxiety treatment market where no new drug class has been approved since Cymbalta in 2007.

The company is sitting on $411.6 million in cash, enough to fund operations into 2028. Stifel initiated with Buy and a $30 target; Piper Sandler went Overweight with $49. Definium hit a 52-week high of $25.63 Monday, up over 300% in the past 12 months.

Cybin / Helus (NYSE: CYBN) — The Next-Gen Contender

Cybin rebranded to Helus in early 2026, reflecting its pivot toward a next-generation psychedelic platform. The company's CYB003, a deuterated psilocybin analog, is designed to offer a shorter, more predictable treatment experience than first-generation psilocybin — a potentially significant commercial advantage in a clinical setting where therapist time is the bottleneck.

While further behind in the regulatory timeline than Compass or Definium, Helus represents the second wave of psychedelic development: molecules engineered specifically for clinical convenience rather than adapted from naturally occurring compounds. Monday: U.S.-listed shares climbed roughly 5-15%.

The Cannabis Angle

For Green Brief readers, the psychedelics EO carries an important subtext. Trump's cannabis rescheduling order from December 2025 has stalled at the DEA with no final decision. The psychedelics order uses the same medical-first, science-driven framework that cannabis advocates have been pushing — physician-led protocols, clinical research, compassionate use pathways. As one industry analyst put it, the psychedelic pathway is a model cannabis advocates should be studying and adopting more aggressively.

The parallel is instructive but cuts both ways. Psychedelics are moving faster precisely because they entered the federal conversation through clinical trials and FDA pathways rather than state-level commercial markets. Cannabis has a multibillion-dollar industry but no FDA-approved pathway for the plant itself. The question isn't whether psychedelics validate the medical-first approach — it's whether cannabis can adapt to use that same playbook before the political window closes.

Big Pharma Is Already Moving

The smart money is noticing. AbbVie acquired Gilgamesh Pharmaceuticals, adding a psychedelic-derived pipeline to a major pharma portfolio. Otsuka announced a $1.225 billion acquisition of methylone developer Transcend Therapeutics. Johnson & Johnson's Spravato (esketamine) is tracking toward $2 billion in annual sales, proving the commercial model for rapid-acting psychiatric treatments.

These deals tell you where the industry is heading. The question for investors isn't whether psychedelics will become approved medicines — it's which compounds clear the regulatory bar first and capture the first-mover advantage in a market where 30% of depression patients fail traditional antidepressants.

The EO doesn't guarantee approval. Phase 3 trials can miss. DEA rescheduling takes time regardless of presidential enthusiasm. But for the first time, the federal government is actively pushing to accelerate rather than obstruct. For the companies that have already done the clinical work, that changes everything.